Six to eight named metabolic centres across six GCC countries, led by KFSH&RC's roughly 120-patient, 15-year experience, concentrate GCC Pompe disease expertise around a handful of institutions, not a broad regional field.
GCC Pompe disease expertise concentrates around a small number of named metabolic centres, not a broad regional field. Enzyme replacement therapy requires metabolic specialist oversight and infusion capacity available at only six to eight centres across all six GCC countries: KAMC and KFSH&RC in Saudi Arabia, AUH and SKMC in the UAE, Hamad Medical Corporation in Qatar, and Sultan Qaboos University Hospital in Oman. The KFSH&RC metabolic genetics programme has treated approximately 120 Pompe patients of all subtypes over 15 years, the region's largest single-centre experience. That kind of concentrated, named-centre infusion network does not happen without an established referral and treatment structure. Our KOL Universe gate (K1) starts by mapping exactly this kind of institutional concentration before any single physician is scored.
That structure changes how AXLRx tiers influence in the GCC. A metabolic physician at a centre with 15 years of accumulated Pompe treatment experience, such as KFSH&RC, carries different scientific weight than one at a lower-volume site, and our Tier Classification gate (K2) scores that distinction directly, alongside GAA enzyme-assay and infusion capability and cross-border referral roles. No named individual enters the workbook without a verification tag. Every KOL identity is checked against live publication records and institutional affiliations, then marked Verified, Industry benchmark, or Requires client validation. A commercial team engaging the wrong tier wastes MSL capacity on a physician with no real influence over regional referral patterns, which is exactly what the K1-K6 gate structure is built to prevent.
The GCC Pompe disease treatment network — six named centres across four countries
| Institution | Country | Role in Network |
|---|---|---|
| King Abdulaziz Medical City (KAMC) | Saudi Arabia | Metabolic disease treatment centre |
| King Faisal Specialist Hospital and Research Centre (KFSH&RC) | Saudi Arabia | Regional referral centre; ~120 patients treated over 15 years |
| AUH | UAE | Metabolic disease treatment centre |
| SKMC | UAE | Metabolic disease treatment centre |
| Hamad Medical Corporation | Qatar | Metabolic disease treatment centre |
| Sultan Qaboos University Hospital | Oman | Metabolic disease treatment centre |
Sources: KFSH&RC Pompe LOPD case series 2015-2022; GCC metabolic disease network registry; KFSH&RC home infusion pilot data 2022; Saudi National Newborn Screening Programme 2022.
What this workbook answers
Every section answers a named commercial question your team is asking, scoped to your asset.
Delivers
- The six-to-eight-centre GCC infusion network across six countries
- KFSH&RC's 120-patient, 15-year experience as the sizing anchor
- K1 KOL Universe Sizing methodology
Delivers
- K2 Tier Classification methodology
- Treatment-volume and infusion-capability weighting
- K3 Scientific Influence scoring inputs
Delivers
- The three-tag verification protocol (Verified/Industry benchmark/Requires client validation)
- Live publication and institutional-affiliation cross-checks
- Why no placeholder name ships unflagged
Custom workbook delivered in 72 hours.
Commission This WorkbookWhat's inside
- Why institutional concentration, not scattergun individual outreach, is the single variable this workbook sizes first
- Pressure-tested against the six-to-eight-centre GCC infusion network case before the rest of the workbook is built out
- Every GCC Pompe disease KOL sized and sourced from institutional-affiliation and treatment-volume data
- KFSH&RC's 120-patient, 15-year experience as the sizing anchor
- Universe boundaries: who counts as a KOL versus a high-volume prescriber
- Scientific-influence scoring across treatment volume, infusion capability, and cross-border referral role
- What separates a Tier 1 KOL from a high-volume community prescriber
- Influence inputs: treatment volume, GAA enzyme-assay and infusion capability, institutional role
- Cross-checked against independent publication and citation data
- Readiness scoring and channel recommendations per KOL
- Sequencing implications for MSL deployment
- Territory-to-KOL coverage map across Saudi Arabia, UAE, Qatar, Oman, and the rest of the GCC
- Where current MSL deployment has gaps
- Multi-market reach for KOLs active beyond their home country, across the wider GCC
- Implications for coordinated versus purely local engagement
- The open KOL-engagement questions your medical affairs team must close
- Structured for an internal alignment session before MSL deployment
Included with every brief
How AXLRx builds this workbook
Prepared by MoatRx analysts.
Every AXLRx KOL workbook is built from live publication records and institutional-affiliation data, not secondary summaries. No KOL name ships without a verification tag.
GCC Pompe disease KOL sources: KFSH&RC Pompe LOPD case series 2015-2022, the GCC metabolic disease network registry, KFSH&RC home infusion pilot data 2022, and the Saudi National Newborn Screening Programme 2022.
- Named GCC treatment-centre list verified against the GCC metabolic disease network registry
- KFSH&RC's 120-patient, 15-year treatment volume verified against the KFSH&RC Pompe LOPD case series 2015-2022
- KFSH&RC home infusion pilot verified against KFSH&RC home infusion pilot data 2022
- Every KOL entry in the underlying workbook carries a three-tag verification status before delivery: Verified, Industry benchmark, or Requires client validation
Frequently asked questions
Commission this workbook
AXLRx delivers KOL mapping workbooks built for medical affairs and commercial teams engaging GCC Pompe disease specialists. Custom workbook in 72 hours.
Specify your indication, geography, and institution scope.
AXLRx analyst confirms institution scope and verification standard before building.
Research-verified KOL workbook in 72 hours with optional analyst readout.